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The purpose of this study was to explore the knowledge, attitudes and practices of health 
professionals working in clinical trials, to pharmacovigilance and adverse drug reaction (ADR) 
reporting.   
 
Methods  
A mixed methods study comprising an online questionnaire disseminated from September to 
November 2018, three semi-structured interviews and four focus groups. The qualitative 
components were conducted with a random sample of questionnaire participants who had 
provided their contact details (n = 24). The qualitative interviews were conducted at a location 
convenient to the participant’s place of work between October and December 2018.  
 
Results  
One hundred and forty-eight participants completed the questionnaire. Study 
coordinators/project managers represented the largest group of participants 28.6% (n=38).  
Poor knowledge or understanding of ADR reporting was the most frequently cited barrier to 
ADR reporting, 75% (n=93). The most common enabler to reporting was having a clear 
understanding of an ADR definition, 85.7% (n=108). Focus group and interview participants 
described having limited staff as a barrier to reporting an ADR. They welcomed the prospect 
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of pharmacovigilance training and indicated that face-to-face training would be preferred to 
provision of online training. 
 
Conclusion 
This study highlights key factors that influence the reporting of ADRs in clinical trials.  
Although the findings are specifically related to the clinical trial environment in Ireland, they 
may provide a useful platform for optimising the future conduct of trials. This research suggests 
that ADR reporting may be improved through provision of enhanced pharmacovigilance 
training to clinical trial staff. 
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Pharmacovigilance is growing in importance in recent years due to the increasing number of 
emerging drugs and has a critical role in clinical trials, post-marketing surveillance  and public 
health [1]. It is defined as the science and the activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other drug-related problem [2]. The 
objectives of pharmacovigilance are to promote the safe and effective use of medicines by 
providing reliable and balanced information for the assessment of the risk-benefit profile of 
medicines and the minimisation of their risk [3].  
The World Health Organisation (WHO) has defined an adverse drug reaction (ADR) as any 
response to a drug which is noxious and unintended, and which occurs at doses normally used 
in man for the prophylaxis, diagnosis or therapy of disease, or for the modification of 
physiological function [1]. It is widely acknowledged that ADRs constitute a major burden at 
the individual and societal level, both as a public health problem and an economic issue [4]. In 
the European Union, it is estimated that ADRs account for 5% of hospital admissions and 
approximately 197,000 deaths per year, resulting in a societal cost of €79 billion [5]. 
Pharmacovigilance is of critical importance to the field of clinical trials and plays a vital role 
in the assessment, monitoring and prevention of ADRs in clinical trials [6]. 
Randomised controlled trials are the gold standard for evaluating the efficacy of new medicines 
before they are released to the market [7]. However, despite the vital importance of drug safety 
information, evidence suggests that clinical adverse effects are adequately reported in only 
39% of clinical trials [8, 9]. It is ultimately the responsibility of the clinical trial principal 
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investigator to ensure optimal ADR reporting in a study [10]. Inconsistency in ADR reporting 
has a number of significant consequences for the conduct of clinical trials and therefore has 
serious implications for patient safety. There are examples of patient safety issues, that were 
not identified during clinical trials, being highlighted in post-marketing surveillance [11, 12]. 
The secondary use of data from randomised controlled trials and meta-analyses can also be 
valuable in the assessment of drug-related harms [13, 14]. This inconsistency in ADR reporting 
also restricts the comparison of ADR rates across trials and it can therefore be extremely 
challenging to systematically review and summarise the literature on ADR reporting [15]. The 
consequences of these deficits vary in severity but collectively represent a challenge to 
effective clinical trial conduct.  The dearth of research examining why ADRs are inadequately 
reported in clinical trials, underlines the need for a study to explore these factors.  Therefore, 
the purpose of this study was to explore the knowledge, attitudes and practices of health 
professionals and researchers working in clinical trials, to pharmacovigilance and ADR 
reporting.  Secondary objectives were to explore the reasons for underreporting of ADRs and 













A convergent parallel mixed methods design was used (Figure 1). The premise of a mixed 
methods approach is that the use of quantitative and qualitative methods in combination 
provides a better understanding of research problems than either approach alone [16]. This 
design entails that the researcher concurrently conducts the quantitative and qualitative 
elements in the same phase of the research process, weighs the methods equally, analyses the 
two components independently, and interprets the results together [16]. In this study, the 
quantitative and qualitative elements were weighted equally and collected in the same phase of 
the research. However, it was necessary to carry out the quantitative data collection first in 
order to identify participants who were willing to participate in the qualitative component of 
the study. The purpose of the qualitative study was also to obtain a deeper and richer 
understanding of the responses from the online questionnaire. 
 
The quantitative responses from an online questionnaire and qualitative responses from semi-
structured interviews and focus groups were collected and analysed separately. The results of 




Figure 1: Convergent parallel mixed methods design 
 
The inclusion criteria for the study were: healthcare professionals, researchers and others 18 
years and older with experience of working in clinical trials in Ireland. The exclusion criteria 
for the study was: experience as a study participant/subject in a clinical trial. 
 
Quantitative methods 
A questionnaire for this study was developed with questions from previous studies [17, 18]. 
The final questionnaire was agreed by consensus of all authors. The questionnaire consisted of 
24 questions in different sections that examined participant demographics such as sex, 
profession, qualifications, role in clinical trials, years of experience specific to clinical trials, 
and knowledge, practice, and attitudes towards the topic. There were a number of questions 
included in the questionnaire that participants could skip if they were not relevant to them. 
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After the first draft of the questionnaire was developed, face validity was tested using a 
convenience sample of five healthcare professionals and academic researchers independent of 
the study team. These responses were not included in the final analysis. Further iterations of 
the questionnaire were then developed until final agreement by all authors. A copy of the 
questionnaire used in this study is available as supplementary material.  
The final question of the questionnaire was optional. If participants expressed an interest in 
attending a semi-structured interview or focus group on the research topic, they were asked to 
provide their contact details, that is name, job title and an email address, for follow-up contact. 
When the questionnaire responses were downloaded, these contact details were uncoupled 
from other questionnaire data and were stored separately in order to maintain the anonymity of 
the data. Only two members of the research team (D.O.R and J.E.) had access to the contact 
details.  
The research team contacted the Health Research Board Clinical Research Coordination 
Ireland (HRB CRCI),  an independent  national network, providing support in the conduct of 
clinical trials across Ireland, to utilise their professional contacts to identify academic 
institutions, hospitals, professional bodies and associations, research networks and charities.  
The research team also assembled a list, based on their professional, academic and research 
networks of other organisations conducting clinical trials in Ireland. 
The online questionnaire (via SurveyMonkey, https://www.surveymonkey.com/) was then 
emailed to healthcare professionals, researchers, data managers, trial coordinators, project 
managers, centre managers and study monitors working in these organisations. As it was not 
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appropriate or feasible to initially make direct contact with potential participants, D.O.R 
contacted a gatekeeper at each organisation who agreed to disseminate the questionnaire within 
their organisation on behalf of the study team. One reminder email was sent to all gatekeepers 
two weeks after initial contact. A link to the questionnaire was also posted in a Tweet on Twitter 
(https://twitter.com/) to capture as many participants as possible. The questionnaire was 
disseminated from September to November 2018.  
Statistical analysis of quantitative data 
Descriptive data analyses were performed using Stata® version 13 (StataCorp, College Station, 
TX, USA). Continuous variables were presented as mean with standard deviation (SD) and 
range, or median with interquartile range (IQR), as appropriate, and categorical variables as 
frequencies (percentage). 
Qualitative methods 
One month after the first questionnaire was completed, semi-structured interviews and focus 
groups were conducted with a random sample of those questionnaire participants who had 
provided their contact details.  When it was not logistically possible to conduct a focus group, 
a one-to-one or phone interview was conducted instead. 
A topic guide was developed based on the questionnaire responses, the literature, and was 
further developed through group discussions by all authors. It was then piloted in a focus group 
consisting of seven academic researchers. The pilot focus group was not included as part of the 
main analysis but served to test and refine the topic guide.  It was also iteratively refined after 
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each focus group and semi-structured interview was transcribed and analysed to pursue 
emerging themes. Examples of the topic guide are available as supplementary material.  
The semi-structured interviews and focus groups were conducted by D.O.R. at a location 
convenient to the participant’s place of work between October and December 2018. All 
interviews and focus groups were audio-recorded, anonymised and transcribed verbatim by one 
researcher (M.K.) and checked for accuracy by another researcher (D.O.R.). They were then 
saved in QSR International NVivo Qualitative Data Analysis Software (V.10.22) to facilitate 
analysis.  Field notes were written and used to facilitate preliminary familiarisation with 
emerging themes immediately after each interview and focus group.   
Qualitative data analysis 
Data were analysed using thematic analysis [19]. Two researchers, M.K. and D.O.R., 
independently reviewed and coded the transcripts. Initial themes were developed by M.K and 
D.O.R and discussed among all authors. The themes subsequently underwent further 
refinement in an iterative manner until all authors agreed upon the final themes.  
 
Standardised reporting guidelines 
The Good Reporting of a Mixed Methods Study (GRAMMS) framework was used to inform 
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In total, 186 participants attempted the survey with 148 complete responses. The response rate 
was not calculated as this was an online survey, and therefore it could not be determined how 
many people received the email or viewed the Tweet. 
Seventy-five per cent (n=104) of participants were female. The occupations of participants 
were nurses/midwives 32.4% (n=44), researchers 22.1% (n=30), pharmacists 18.4% (n=25), 
Consultant Physicians 5.2% (n=7), General Practitioners 2.9% (n=4), non-consultant hospital 
doctors 2.2% (n=3) and others 16.9% (n=23). Those who identified themselves as “others” 
described their clinical trials roles as data managers, pharmacovigilance officers, trial 
coordinators, project managers, centre managers and trial monitors.  
Study coordinators/project managers represented the largest group of participants 28.6% 
(n=38), followed by research nurses 17.3% (n=23) and others including research pharmacists, 
clinical trial pharmacists, and study doctors, 17.3% (n=23) (See supplementary material). The 








Ninety-eight per cent of participants (n=129) were familiar with the term pharmacovigilance. 
Almost all participants were familiar with the following terms associated with the practice of 
pharmacovigilance: monitoring and evaluating adverse events (94.5%, n=121), promoting safe 
and effective use of medicines (89.1%, n=114), benefit-risk assessment of medicines (88.3%, 
n=113), risk management of medicines (84.4%, n=108). 
Participants were provided with a definition for an adverse drug reaction and were asked to 
describe their understanding of it on a scale where 1 = poor and 10 = excellent. The median 
(IQR) score was 8 (7,10). Approximately 72.3% (n=94) of participants reported having 
adequate knowledge on how to report an ADR.  
Over half of participants 55.0% (n=71) were involved in the reporting of ADRs in clinical 
trials. For those involved in ADR reporting, 80% (n=56) identified the ADRs at participant 
follow-up visits, 71.4% (n=50) from participant’s self-report, and 68.6% (n=48) from 
participant interview (in person, or by phone). The majority of those involved in ADR reporting 
(80%, n=56) reported the ADR to the study sponsor.  
Table 1 shows the barriers and enablers/facilitators to reporting ADRs in clinical trials. The 
most frequently cited barriers were poor knowledge or understanding of ADR reporting 75% 
(n=93), lack of practical guidance about ADR reporting 59.7% (n=74) and ambiguity and 
inconsistency surrounding the definition of ADRs (i.e. too many definitions) 56.5% (n=70). 
The most common enablers/facilitators were clear understanding of ADR definition 85.7% 
(n=108), good knowledge of how to assess a clinical trial ADR 84.9% (n=107) and access to 
an online reporting portal 75.4% (n=95).  
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Table 1: Barriers and enablers/facilitators to reporting ADRs in clinical trials 
Barriers % (n) 
Poor knowledge/understanding of ADR reporting  75.0 (93) 
Lack of practical guidance about ADR reporting  59.7 (74)   
Ambiguity and inconsistency surrounding the definition of ADRs (i.e. too 
many definitions)  
56.5 (70) 
Time restraints  44.4 (55) 
Lack of agreement regarding the most appropriate strategies of ADR 
assessment  
36.3 (45) 
Lack of perceived importance of ADR reporting  36.3 (45) 
Concerns about the implications of reporting the ADR to the trial 
regulator  
26.5 (33) 
Resistance/perceived resistance from other stakeholders in the clinical 
trial  
25.0 (31) 
Other  12.0 (14) 
  
Enablers  % (n) 
Clear understanding of ADR definition 85.7 (108) 
Good knowledge of how to assess a clinical trial ADR  84.9 (107) 
Online reporting portal  75.4 (95) 
Perceived importance of ADR reporting by researchers  71.4 (90) 
Designated reporting person ( e.g. trained in the technical requirements of 
electronic reporting in EudraVigilance)  
71.4 (90) 
Availability of reporting criteria specific to ADRs    68.3 (86) 





Participants recognised the importance of receiving training on reporting ADRs in clinical trials 
and 58.7% (n=74) have attended formal workplace training (e.g. attended workshops, seminars, 
lectures) on this topic. The majority of participants 88.9% (n=112) reported they would avail 
of training in reporting ADRs in clinical trials if it was available. Participants indicated they 
would prefer ADR training via face-to-face workshops 62% (n=70), online courses 52.2% 
(n=59), webinars 30.1% (n=34), seminars 30.1% (n=34) and lectures 26.6% (n=30). 
 
 
Qualitative Results  
 
The four focus groups and three semi-structured interviews ranged from 43 min to 76 min in 
length (mean length 53 min). The mean duration of participant’s experience in clinical trials 
was 11 years. The characteristics of the 24 participants that attended the focus groups and semi-












Understanding of the terms Pharmacovigilance and Adverse Drug Reaction 
All participants provided a clear and accurate description of the term pharmacovigilance. Some 
participants quoted the WHO definition. Others demonstrated understanding by describing the 
term using their own words. 
 “So the definition, the science and activities relating the assessment and detection of adverse 
reactions in clinical trials and any medicinal product.” 
(Participant 20, Pharmacovigilance Officer, Focus group 4) 
“…The clue is in the name, it’s vigilance. It’s looking at the safety of a drug over its lifetime…” 
(Participant 7, Quality Manager, Focus group 2) 
The majority of participants correctly defined the term ADR, with some using descriptions 
very similar to the International Conference on Harmonisation definition. 
“…it’s essentially anything adverse that can happen to a patient as a result, a direct result of 
the pharmaceutical product in question…” 
(Participant 22, Principal Investigator, Semi structured interview 1) 
“A noxious or an unintended response to a drug at any dose.” 






Responsibility for reporting  
Participants emphasised the importance of the principal investigator being actively involved in 
the conduct of the trial. Participants reported that other trial staff should not have to persuade 
the principal investigator to carry out their tasks. It was stressful for staff if the principal 
investigator was not willing to engage with them. Participants also highlighted that some 
principal investigators didn’t place enough emphasis on their role and should prioritise this 
responsibility. This is particularly relevant as ADRs require immediate reporting to the study 
sponsor and it is the legal responsibility of the principal investigator to carry out this role. 
“…if an investigator is not really hands on, then they shouldn’t be doing studies. It’s that 
important... It shouldn’t be up to the nurse to be cajoling them or twisting their arm or 
whatever... It can be sometimes seen as not that terribly important and the investigators, if they 
want to do clinical trials, they need to prioritise this.”  
(Participant 12, Study Physician, Focus group 3)  
“It's quite stressful actually, it’s very stressful, I’ve seen coordinators, nurses getting quite 
stressed if a PI is too busy to engage and runs away. It’s not a nice situation…” 






ADR reporting process 
Enablers for reporting  
The majority of participants indicated that the reporting of adverse events involved a paper 
format. Participants agreed that an electronic form would be the preferred option for reporting.  
“I process the SAEs when they come in but they’re still paper so I would definitely love an 
electronic database that sites could report…...” 
(Participant 17, Quality Manager, Focus group 4) 
Participants described a guidance tool as being very useful when completing the reporting 
form. This practical guide would streamline the reporting process and reduce the risk of errors 
occurring.  
 “Some sponsors would sometimes supply a guidance tool on how to fill out the reporting form 
which can be really useful as well.” 
(Participant 16, Research Nurse, Focus group 3) 
Barriers to reporting 
Participants described the challenge of having a limited resource of staff, in terms of numbers 
of staff, experience level and the dedicated time for the staff member to report an ADR, 
especially when reporting suspected unexpected serious adverse reactions (SUSARs) to the 
relevant authorities. This was particularly stressful if a member of the team was unavailable 
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when a SUSAR report was due for submission. The process of collecting the relevant 
information and reporting the event was described as time consuming. 
“ … if you get an ADR that’s obviously serious and unexpected and it needs to go to 
EudraVigilance or the HPRA (The Health Products Regulatory Authority) and ethics that you 
know with those tight timelines and in that environment where you don’t have a big nice PV 
team you’re looking at a situation where you could be on annual leave and have to report a 
SUSAR so I would say yeah, in my environment now that’s actually really challenging.  
(Participant 17, Quality Manager, Focus group 4) 
“I think it’s important, to make sure staff have enough time to do that data capture and 
reporting… because there’s an awful lot of time, it’s not just the patient visit. It’s all the 
reporting afterwards as well, so it is very important.” 
(Participant 15, Clinical Nurse Manager, Focus group 3) 
Although participants acknowledged the importance of reporting adverse events, they were 
also aware of the possible implications associated with reporting. This could be associated with 
an abundance of follow-up queries for the reporter to address until the event is closed out.  
“ ... Like anything we report SAEs, AEs, is followed by multiple emails, multiple questionnaires, 
multiple follow-up letters so… we do it, we know we have to do it but it’s like oh no we have to 
report this and you’re just waiting for this wave of questions to come back to you then.” 




Relationship with stakeholders 
Working with an experienced member of the trial team was described as being very beneficial. 
Experienced staff were a useful resource for addressing queries that their colleagues may have. 
This was regarded as being important as it gave staff more confidence when dealing with a 
principal investigator.  
 “ … so if you work with someone who is more experienced then you can bounce things off 
them and I think that’s really, really important when it comes to … things that you might not 
be sure of, that a more experienced research nurse would be able to help out with and then 
you’d have more confidence going to the PI.” 
(Participant 13, Study Monitor, Focus group 3) 
 
Education and training  
Some participants reported that previous pharmacovigilance training was well received by 
attendees and they welcomed further educational events on this topic as it was considered 
important.  
“We did a pharmacovigilance training session some time ago and there was a very good 
attendance at it and people felt that it was quite helpful, so I think we probably need to do more 
of them….” 
(Participant 12, Study Physician, Focus group 3)  
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Participants suggested face-to-face training would be more beneficial compared to an online 
version, as the latter format of training could sometimes be time restrictive. Face-to-face 
training enhanced the learning experience as it provided an opportunity to interact and discuss 
pharmacovigilance related matters with the facilitator and fellow attendees. 
“You see I find face-to-face works really well but I know there’s a big push for blended learning 
and webinars, a webinar could work but then you tend to have to keep them very time limited 
because it tends to be pushed into three quarters of an hour or something like that…” 
(Participant 18, Clinical Nurse Manager, Focus group 4) 
“And you can ask questions then or give specific examples of you know instances you’ve come 
across in pharmacovigilance and just get another opinion, you can’t do that online really.” 
(Participant 13, Study Monitor, Focus group 3) 
Participants suggested that an accredited course such as Good Clinical Practice (GCP) training 
was very beneficial especially for principal investigators and sub-investigators as it provided a 
platform for outlining their roles and responsibilities within a trial. 
“I think having foundation knowledge in relation to having GCP training, an accredited course 
is very important so that the investigator and sub-investigators know their responsibilities and 
therefore they will always have a reference text in knowing their responsibilities.” 






This study used a mixed methods approach to explore the factors that influence the reporting 
of ADRs in clinical trials. Participants reported having a good knowledge and understanding 
of pharmacovigilance and ADRs. Key enablers to ADR reporting were having a clear 
understanding of an ADR definition, knowledge of how to assess a clinical trial ADR, having 
access to an online reporting portal and the perceived importance of ADR reporting by 
researchers. Key barriers to ADR reporting were having poor knowledge of ADR reporting, 
lack of practical guidance, time restraints, lack of perceived importance, resistance from other 
stakeholders in the trial, implications of reporting and having limited staff resources. 
Pharmacovigilance training was valued by the participants.  
It is imperative that all stakeholders involved in clinical trials have a comprehensive 
understanding of the key concepts associated with pharmacovigilance and drug safety. This 
can optimise the key aspects of preventing, recognising, managing and reporting of ADRs. In 
non-clinical trial settings, it has been reported that fewer than half of participants were familiar 
with these concepts [21, 22]. It is evident from the findings of the present study that the 
population was very knowledgeable about clinical trials and had a clear understanding of the 
term’s pharmacovigilance and ADR. This is very reassuring given the importance of these 





Training and education on ADR reporting in clinical trials was emphasised by participants. 
Findings from the literature suggest that educating investigators, sponsors and others involved 
in clinical trials on the best practices with regards to relating an adverse event to a medicinal 
product can optimise the consistency of the reporting process [23]. Although fifty-per cent of 
participants in the questionnaire indicated that online courses would be their preferred type of 
training, those who were interviewed indicated a preference for face-to-face training over the 
provision of online training. Wutoh et al. carried out a review of internet-based continuing 
medical education. The study demonstrated that this method of education delivery is just as 
effective at generating knowledge compared to traditional formats. However, there is little 
evidence to suggest the positive changes in knowledge are translated into changes to practice 
[24]. A future study could compare the impact of face-to-face training to an online course with 
regards to ADR reporting. 
Interestingly, interview participants identified that Good Clinical Practice (GCP) training is 
very important for investigators throughout their career. It is imperative that all personnel 
involved in regulated clinical trials are trained on international standards such as GCP [10]. 
Although pharmacovigilance and ADR reporting are included in GCP training, clinical trial 
staff expressed a desire for additional pharmacovigilance training.  
A key finding from the interviews indicated that working with an experienced member of the 
trial team was beneficial. George et al. highlighted that the quality and experience of a clinical 
research team are considered important components to the success of adverse event reporting, 
particularly in early-phase cancer trials [23]. This should be a key consideration for clinical 
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trialists when establishing a trial team. In addition to pharmacovigilance training, a formal 
mentorship programme for early-career researchers may be beneficial during the set-up of the 
clinical trial.   
The potential role of an online reporting portal was emphasised in this study with participants 
suggesting it would optimise the reporting of ADRs in clinical trials. It is documented that  
traditional resources used for ADR reporting such as paper forms can lead to inaccuracies in 
data collection and inefficiencies in the reporting process [25]. The use of clinical trial 
electronic portals has gained popularity in recent years. Electronic portals offer the opportunity 
to reduce time and costs associated with paper-based reports. They also provide the benefit of 
a security measure with document management through the use of password protected log-in 
[26]. Given the strong preference for this method of reporting and with evidence supported 
from the literature, online ADR reporting should be recommended in all future trials. It is likely 
that more efficient and better reporting will result, and this may lead to the overall improvement 
in patient outcomes.  
The lack of practical guidance was reported as the most common barrier to ADR reporting 
among those who completed the questionnaire. Responses from the interviews indicated that a 
guidance document would be very beneficial for staff when completing the reporting form.  
This attests to the need for the sponsor to engage with the PI during the development of the 
study protocol to ensure that the most relevant and practical resources are used to streamline 
the reporting process.  
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Time restraints and limited staff numbers were highlighted as a key barrier to ADR reporting 
in this study. George et al. support this finding and described the time-consuming process for 
an investigator to gather sufficient data for review and determine the relationship between the 
adverse event and study treatment [23]. The qualitative findings reported the challenge of 
having limited staff to report an ADR. Mirbaha et al. highlighted that a lack of human resources 
was one of the factors that hampered the reporting of adverse drug events [27].   
A lack of perceived importance of ADR reporting and resistance from other stakeholders in the 
trial were considered as barriers to reporting. Participants reported their frustration and cited 
the challenge of working with principal investigators who fail to bear responsibility for their 
role. In many cases, principal investigators have busy clinical schedules, and for some, this 
may infringe on time to carry out their research role. It is important that investigators 
successfully meet all research expectations when conducting a clinical trial. They should be 
aware of all events especially serious or unexpected events as these need expedited reporting 
to the relevant authorities. [28]. According to the principles of the International Conference on 
Harmonisation GCP one of the key responsibilities of the PI is to ensure that the site reports an 
adverse event immediately to the study sponsor on becoming aware of it [29]. One solution 
may be to delegate certain responsibilities and tasks to sub-investigators. The sub-investigator 
can deputise for the PI for phone calls, laboratory result reviews, adverse event assessments, 
informed consent, and be prepared to answer questions on behalf of the PI if they are 
unavailable [30] . 
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Concerns regarding the implications of reporting the ADR to the trial regulator was also 
considered a barrier. Participants who were interviewed indicated their concerns regarding the 
possible implications associated with reporting such as addressing multiple follow-up queries.  
Responding to queries can be time consuming and become a burden especially for clinical trial 
sites that are under resourced with staff. This can contribute to an under-reporting of adverse 
events and therefore lead to a false perception of the benefit-risk ratio of drugs which can affect 
many stakeholders including patients, clinicians, drug developers and regulators [31, 32]. 
Further work should be carried out to identify the most efficient ways to streamline the follow-
up query process. It is essential to obtain the views from all the relevant stakeholders in this 
process including principal investigators, representatives from study sponsors and competent 
authorities in order to design a fit-for-purpose electronic system that maintains the integrity 
and detail required of a clinical trial reporting system while meeting the needs of clinical trial 
personnel. 
 
Implications for policy and practice 
The findings from this study are important for researchers conducting future clinical trials as it 
highlights barriers and enablers to ADR reporting. The findings also suggest that additional 
training and support are required for effective ADR reporting and monitoring. Academic 
institutions should consider incorporating content on pharmacovigilance and ADR reporting 
into the curriculum for undergraduate healthcare programmes, especially in pharmacy, nursing 
and medicine. The WHO pharmacovigilance core curriculum for university teaching have 
formulated competencies and key clinical aspects that can be integrated into existing courses 
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such as pharmacology and pharmacotherapy or used as a stand-alone course [33]. The WHO 
International Society of Pharmacovigilance have created a comprehensive, detailed and 
balanced curriculum for pharmacovigilance education [34]. Rosebraugh et al. developed an 
ADR quality reporting education intervention program presented to 4th year medical students 
on a clinical pharmacology rotation. The study demonstrated that the 15-minute intervention 
significantly improved the overall quality of ADR reporting [35]. Educating students at 
university level may improve their knowledge about the safety of medicines and equip them 
with the relevant skills for the safer use of medicines throughout their career [36, 37].  
 
Strengths and limitations 
This is the first national study on pharmacovigilance and ADR reporting in clinical trials in 
Ireland. The use of a mixed methods approach which combined quantitative and qualitative 
data facilitated a richer analysis. The qualitative interviews were arranged with participants 
over a three-month period and this facilitated prolonged engagement with the data. The 
generalisability of the study findings may be limited by the inability to calculate a response 
rate. However, the broad inclusion criteria and background of participants with an extensive 
representation of clinical trial expertise help ensure that the findings reflect the most important 
factors that influence the reporting of ADRs in clinical trials in Ireland. 
While 75% of participants were female, this may simply reflect the gender balance within the 
clinical trial environment in Ireland. The focus groups were organised at locations and at times 
to maximise participation, however despite these efforts, no PI was available to attend due to 
their workload and time pressures. Therefore, the qualitative interviews were only conducted 
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with PIs. The qualitative data collection was conducted by one researcher (D.O.R), however 
dependability was enhanced by using a multidisciplinary team input: pharmacists (D.O.R., 
M.K., K.A.W., M.B.), epidemiologist (F.S.) and physician (J.E.) during data analysis 
(investigator triangulation). 
Conclusion 
This study highlights key factors that influence the reporting of ADRs in clinical trials. It is 
imperative that all stakeholders involved in clinical trials have a comprehensive understanding 
of the key terms associated with ADR reporting. Enhanced pharmacovigilance training should 
be recommended to all clinical trial staff as this may improve ADR reporting. Online reporting 
offers a more efficient way of optimising the reporting process. Principal investigators should 
consider delegating responsibility to sub-principal investigators and other members of the team 
where necessary.   
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